Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood disorders like sickle cell disease and beta thalassemia shown that CRISPR products could provide a functional cure just months after initiation of treatment. In other labs, the use of CRISPR has proven effective in combatting nearly all strands of Coronavirus, including SARS-COV2, the cause of COVID-19.
Related ETF: ARK Genomic Revolution Multi-Sector ETF (ARKG)
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, sign up or start a free trial .